Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy

Journal of Clinical Oncology

Volumn 31, Issue 20, 2013, Pages 2627-2633

  Hershman, Dawn L ^a   Unger, Joseph M ^b   Crew, Katherine D ^a   Minasian, Lori M ^d   Awad, Danielle ^a   Moinpour, Carol M ^c   Hansen, Lisa ^e   Lew, Danika L ^b   Greenlee, Heather ^a   Fehrenbacher, Louis ^f   Wade, James L ⁱ   Wong, Siu Fun ^g   Hortobagyi, Gabriel N ^j   Meyskens, Frank L ^h   Albain, Kathy S ^k  

^a NewYork Presbyterian Hospital   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^f KAISER PERMANENTE   (United States)

^g LOMA LINDA UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Central Illinois Community Clinical Oncology Program   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k LOYOLA UNIVERSITY CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; DOCETAXEL; LEVACECARNINE; NUTRITION SUPPLEMENT; PACLITAXEL; ACETYLCARNITINE; TAXOID;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CONTROLLED STUDY; DRUG INDUCED DISEASE; DYSKINESIA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MIDDLE AGED; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; VOMITING; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FOLLOW UP; MASTECTOMY; METHODOLOGY; MULTIVARIATE ANALYSIS; NERVE REGENERATION; PATHOLOGY; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

ACETYLCARNITINE; ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE REGENERATION; PERIPHERAL NERVOUS SYSTEM DISEASES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAXOIDS; TREATMENT OUTCOME;

EID: 84883878724     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.8738     Document Type: Article

References (36)

1. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
2. Pazdur R, Kudelka AP, Kavanagh JJ, et al: The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19:351-386, 1993
3. Hershman DL, Weimer LH, Wang A, et al: Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125:767-774, 2011
4. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
5. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
6. Hegarty A, Portenoy RK: Pharmacotherapy of neuropathic pain. Semin Neurol 14:213-224, 1994
7. Bieber LL: Carnitine. Annu Rev Biochem 57: 261-283, 1988
8. Kelly GS: L-carnitine: Therapeutic applications of a conditionally-essential amino acid. Altern Med Rev 3:345-360, 1998
9. Pisano C, Pratesi G, Laccabue D, et al: Paclitaxel and cisplatin-induced neurotoxicity: A protective role of acetyl-L-carnitine. Clin Cancer Res 9:5756-5767, 2003
10. De Grandis D, Minardi C: Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: A long-term, randomised, double-blind, placebo-controlled study. Drugs R D 3:223-231, 2002
11. Di Giulio AM, Gorio A, Bertelli A, et al: Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals. Int J Clin Pharmacol Res 12:243-246, 1992
12. Famularo G, Moretti S, Marcellini S, et al: Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucle-oside analogues. AIDS 11:185-190, 1997
13. Bianchi G, Vitali G, Caraceni A, et al: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746-1750, 2005
14. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
15. Cella D, Peterman A, Hudgens S, et al: Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-taxane). Cancer 98:822-831, 2003
16. Kottschade LA, Sloan JA, Mazurczak MA, et al: The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. Support Care Cancer 19:1769-1777, 2011
17. Rao RD, Michalak JC, Sloan JA, et al: Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110-2118, 2007
18. Rao RD, Flynn PJ, Sloan JA, et al: Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112:2802-2808, 2008
19. Moore DH, Donnelly J, McGuire WP, et al: Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207-4213, 2003
20. Barton DL, Wos EJ, Qin R, et al: A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19:833-841, 2011
21. Smith TJ, Coyne PJ, Parker GL, et al: Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage 40:883-891, 2010
22. Seifried HE, Anderson DE, Sorkin BC, et al: Free radicals: The pros and cons of antioxidants - Executive summary report. J Nutr 134:3143S-3163S, 2004
23. Norman HA, Butrum RR, Feldman E, et al: The role of dietary supplements during cancer therapy. J Nutr 133:3794S-3799S, 2003 (suppl 1)
24. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers: The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029-1035, 1994
25. Bairati I, Meyer F, Gélinas M, et al: A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481-488, 2005
26. Klein EA, Thompson IM Jr, Tangen CM, et al: Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306:1549-1556, 2011
27. Cassileth BR, Vickers AJ: High prevalence of complementary and alternative medicine use among cancer patients: Implications for research and clinical care. J Clin Oncol 23:2590-2592, 2005
28. Greenlee H, Gammon MD, Abrahamson PE, et al: Prevalence and predictors of antioxidant supplement use during breast cancer treatment: The Long Island Breast Cancer Study Project. Cancer 115:3271-3282, 2009
29. Nesheim MC: What is the research base for the use of dietary supplements? Public Health Nutr 2:35-38, 1999
30. Xiao WH, Zheng H, Bennett GJ: Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 203:194-206, 2012
31. Zheng H, Xiao WH, Bennett GJ: Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 232:154-161, 2011
32. Xiao W, Naso L, Bennett GJ: Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropa-thies. Pain Med 9:505-517, 2008
33. Jin HW, Flatters SJ, Xiao WH, et al: Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 210: 229-237, 2008
34. Cruciani R, Dvorkin E, Homel P, et al: L-Carnatine supplementation improves fatigue, mood and sleep in cancer patients with fatigue and carnatine deficiency. J Clin Oncol 24:490s, 2006 (suppl; abstr 8588)
35. Kopec J, Land S, Cecchini R: Validation of self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Supp Oncol 4:W1-W8, 2006
36. Postma TJ, Aaronson NK, Heimans JJ, et al: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 41:1135-1139, 2005